Worldwide patient experience with Esbriet

Esbriet is used in more than 40 countries worldwide 2*

 

MORE THAN

PATIENTS HAVE TAKEN PIRFENIDONE WORLDWIDE SINCE 2011 2

 

The safety of pirfenidone has been evaluated in more than 1400 subjects, with over 170 subjects exposed to pirfenidone for more than 5 years in clinical trials 1
Please see the Esbriet safety and tolerability profile.

*Countries include Albania, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Ecuador, Finland, France, Georgia, Germany, Greece, Hong Kong (special administrative region), Iceland, Ireland, Israel, Italy, Kosovo, Kuwait, Luxembourg, Macao (special administrative region), Malaysia, Montenegro, Myanmar, the Netherlands, New Zealand, Norway, Oman, Qatar, Russia, Saudi Arabia, Serbia, Singapore, Spain, Sweden, Switzerland, Turkey, Ukraine, the United Arab Emirates, the United Kingdom, the United States, Uruguay.

ESBRIET CLINICAL EFFICACY   

Learn how Esbriet may help your patients maintain more lung function by reducing lung function decline 

ESBRIET SAFETY AND TOLERABILITY 

Learn more about the safety and tolerability profile of Esbriet

PERSONALIZED SUPPORT

Find out how Esbriet supports your patients with education and inspiration to help them get the most out of therapy